Get the Stockscreener App
28.80
1.40%
-0.41
After Hours:
27.43
-1.37
-4.76%
Quidelortho Corporation stock is traded at $28.80, with a volume of 1.20M.
It is down -1.40% in the last 24 hours and down -14.40% over the past month.
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
See More
Previous Close:
$29.21
Open:
$29.04
24h Volume:
1.20M
Relative Volume:
1.03
Market Cap:
$1.96B
Revenue:
$2.74B
Net Income/Loss:
$-441.40M
P/E Ratio:
-4.4037
EPS:
-6.54
Net Cash Flow:
$13.00M
1W Performance:
-1.74%
1M Performance:
-14.40%
6M Performance:
+21.83%
1Y Performance:
-30.55%
1-Day Range:
$27.48
$29.40
1-Week Range:
$27.48
$30.50
52-Week Range:
$19.50
$43.92
Quidelortho Corporation Stock (QDEL) Company Profile
Name
Quidelortho Corporation
Sector
Industry
Phone
(858) 552-1100
Address
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Compare QDEL vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corporation
|
28.80 | 1.98B | 2.74B | -441.40M | 13.00M | -6.54 |
|
ABT
Abbott Laboratories
|
113.59 | 195.24B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
363.70 | 138.08B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
101.08 | 130.02B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
73.47 | 110.11B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
79.33 | 44.71B | 5.88B | 1.34B | 799.60M | 2.3489 |
Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-25 | Downgrade | Citigroup | Buy → Neutral |
| May-08-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Sep-19-24 | Resumed | UBS | Neutral |
| Sep-05-24 | Upgrade | Craig Hallum | Hold → Buy |
| Mar-04-24 | Downgrade | UBS | Neutral → Sell |
| Feb-14-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-14-22 | Upgrade | UBS | Sell → Neutral |
| Sep-19-22 | Initiated | Citigroup | Neutral |
| Jul-20-22 | Initiated | UBS | Sell |
| Jun-17-22 | Resumed | JP Morgan | Neutral |
| Feb-22-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-12-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-26-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-23-18 | Resumed | Raymond James | Strong Buy |
| Mar-08-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-18 | Reiterated | Barclays | Overweight |
| Jan-04-18 | Upgrade | CL King | Neutral → Buy |
| Sep-19-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-18-17 | Upgrade | William Blair | Mkt Perform → Outperform |
| Apr-25-17 | Reiterated | Canaccord Genuity | Hold |
| Feb-17-17 | Initiated | CL King | Neutral |
| Dec-16-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-13-16 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-18-16 | Reiterated | Barclays | Overweight |
| Feb-09-16 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jan-08-16 | Reiterated | Canaccord Genuity | Buy |
| Dec-14-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-02-15 | Initiated | Barclays | Overweight |
| Jul-31-13 | Reiterated | Canaccord Genuity | Buy |
| Mar-03-11 | Downgrade | Wedbush | Outperform → Neutral |
View All
Quidelortho Corporation Stock (QDEL) Latest News
QuidelOrtho Q4 2025 slides: Revenue beats expectations despite 27% EPS drop - Investing.com
QuidelOrtho Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: QuidelOrtho Q4 2025 misses EPS, stock dips - Investing.com
QDEL Projects Significant Revenue Growth by FY26 - GuruFocus
QuidelOrtho (QDEL) Sees Mixed Growth Across Business Segments - GuruFocus
QuidelOrtho (QDEL) Exceeds Q4 Revenue Expectations with Diversif - GuruFocus
QuidelOrtho (QDEL) Projects Steady Covid-19 Revenue Through FY25 - GuruFocus
QuidelOrtho (QDEL) Projects Strong Financial Performance for FY2 - GuruFocus
QuidelOrtho (QDEL) CFO Announces Retirement Plans - GuruFocus
QuidelOrtho (QDEL) Projects FY26 Tax Rate at 24% - GuruFocus
QuidelOrtho Q4 2025 Earnings: Revenue & Profit Beat, 2026 Outlook CautiousNews and Statistics - IndexBox
QuidelOrtho Q4 Earnings Fall, Revenue Rises; Issues Guidance - marketscreener.com
QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
QuidelOrtho (NASDAQ:QDEL) Exceeds Q4 CY2025 Expectations - Finviz
QuidelOrtho Q4 results beat on both lines, but issues weak 2026 EPS guidance - MSN
QuidelOrtho: Fourth Quarter Financial Highlights - Bitget
QuidelOrtho: Q4 Earnings Snapshot - kens5.com
QuidelOrtho (NASDAQ:QDEL) Issues Earnings Results - MarketBeat
Earnings Flash (QDEL) QuidelOrtho Corporation Posts Q4 Adjusted EPS $0.46 per Share, vs. FactSet Est of $0.42 - marketscreener.com
QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results - PR Newswire
QuidelOrtho (NASDAQ:QDEL) Surpasses Projections for Q4 CY2025 - Bitget
Weekly Recap: Is QuidelOrtho Corporation a turnaround storyJuly 2025 Snapshot & Weekly High Momentum Picks - baoquankhu1.vn
Why is QuidelOrtho Corporation stock going downJuly 2025 Selloffs & Weekly Chart Analysis and Guides - mfd.ru
Will QuidelOrtho Corporation benefit from rising consumer demandVolume Spike & Technical Buy Zone Confirmations - mfd.ru
Earnings To Watch: QuidelOrtho (QDEL) Reports Q4 Results Tomorrow - Yahoo Finance
Earnings Preview: QuidelOrtho (QDEL) Q4 Earnings Expected to Decline - Eastern Progress
Earnings preview: QuidelOrtho (QDEL) Q4 earnings expected to decline - MSN
Aug Opening: What are the future prospects of iSpecimen Inc2025 Sector Review & Verified Momentum Stock Alerts - baoquankhu1.vn
QuidelOrtho director Matthew W. Strobeck to step down after annual meeting - Investing.com Nigeria
QuidelOrtho Announces Board Director Matthew Strobeck’s Departure - TipRanks
QuidelOrtho director Matthew W. Strobeck to step down after annual meeting By Investing.com - Investing.com South Africa
Does QuidelOrtho Corporation offer margin of safety2025 Momentum Check & Fast Gaining Stock Reports - baoquankhu1.vn
RBC Capital Raises PT on QuidelOrtho Corporation From $60 to $62, Keeps Buy Rating - MSN
QuidelOrtho: EBIT Margins In Focus As We Approach Q4 Earnings Release (NASDAQ:QDEL) - Seeking Alpha
QuidelOrtho (QDEL) to Release Earnings on Wednesday - MarketBeat
QuidelOrtho Corporation (NASDAQ:QDEL) Given Average Rating of "Hold" by Brokerages - MarketBeat
QuidelOrtho Receives Excellence Services Label in EMEA and Two Stevie® Awards - Barchart.com
Ballast Asset Management LP Has $2.36 Million Stock Holdings in QuidelOrtho Corporation $QDEL - MarketBeat
QuidelOrtho Faces Profitability Pressures Yet Trades At Steep Valuation Discount - simplywall.st
Aug Final Week: Whats the fair value of NextEra Energy Inc Preferred Security stockEarnings Growth Summary & High Conviction Buy Zone Picks - baoquankhu1.vn
Gagnon Securities LLC Grows Stock Holdings in QuidelOrtho Corporation $QDEL - MarketBeat
Is QuidelOrtho (QDEL) A Value Opportunity After Steep Multi‑Year Share Price Declines - simplywall.st
QuidelOrtho Corporation (QDEL) Investor Outlook: Analyzing a Potential 33.66% Upside in the Healthcare Sector - DirectorsTalk Interviews
3 Reasons to Sell QDEL and 1 Stock to Buy Instead - Finviz
3 Reasons QDEL is Risky and 1 Stock to Buy Instead - Finviz
Is QuidelOrtho’s (QDEL) Distress-Zone Z-Score Overshadowing Its Core Diagnostics Story? - simplywall.st
QuidelOrtho (NASDAQ:QDEL) Shares Down 7.9%Time to Sell? - MarketBeat
QuidelOrtho (QDEL) Valuation Check After Steep Share Price Slide And Rising Financial Distress Concerns - simplywall.st
Strengthening the blood supply: Awareness, challenges and donor impact - Finviz
William Blair Maintains QuidelOrtho(QDEL.US) With Hold Rating - 富途牛牛
Why climate disasters and O-type demand are stressing the blood supply - Stock Titan
Quidelortho Corporation Stock (QDEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.61%
0.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):